Validation of the Usefulness of the Diameter Reduction, Spiral Shape, Flow Impairment, or Adverse Morphology Classification System in Real-World Clinical Practice-Reference-Cited by-同舟云学术

Validation of the Usefulness of the Diameter Reduction, Spiral Shape, Flow Impairment, or Adverse Morphology Classification System in Real-World Clinical Practice

Published:2024-02-01 Issue:2 Volume:31 Page:148-157
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Yamada Takehiro¹,Tokuda Takahiro²,Yoshioka Naoki³,Koyama Akio⁴,Nishikawa Ryusuke⁵,Shimamura Kiyotaka⁶,Tsuruoka Takuya⁷,Mitsuoka Hiroki⁸,Aoyama Takuma¹

Affiliation:

1. Division of Cardiology, Central Japan International Medical Center

2. Division of Cardiology, Nagoya Heart Center

3. Division of Cardiology, Ogaki Municipal Hospital

4. Division of Vascular surgery, Toyota Memorial Hospital

5. Division of Cardiology, Kyoto University Hospital

6. Division of Cardiology, Shizuoka General Hospital

7. Division of Vascular surgery, Ichinomiya Municipal Hospital

8. Division of Vascular surgery, Aichi Medical University Hospital

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/31/2/31_64335/_pdf

Reference23 articles.

1. 1) Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, Schroeder H, Prem JT, Holden A, Popma J, Jaff MR, Diaz-Cartelle J, Müller-Hülsbeck S; IMPERIAL investigators: A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet, 2018; 392: 1541-1551

2. 2) Gouëffic Y, Torsello G, Zeller T, Esposito G, Vermassen F, Hausegger KA, Tepe G, Thieme M, Gschwandtner M, Kahlberg A, Schindewolf M, Sapoval M, Diaz-Cartelle J, Stavroulakis K; EMINENT Investigators: Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial. Circulation, 2022; 146: 1564-1576

3. 3) Iida O, Takahara M, Soga Y, Yamaoka T, Fujihara M, Kawasaki D, Ichihashi S, Kozuki A, Nanto S, Sakata Y, Mano T; CAPSICUM Investigators: 1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration. JACC Cardiovasc Interv, 2022; 15: 630-638

4. 4) Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR; IN.PACT SFA Trial Investigators: Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation, 2015; 131: 495-502

5. 5) Yoshioka N, Tokuda T, Koyama A, Yamada T, Nishikawa R, Shimamura K, Takagi K, Morita Y, Tanaka A, Ishii H, Morishima I, Murohara T; on the ASIGARU PAD investigators: Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons. Heart Vessels, 2022; 37: 555-566